chr3996
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00697879)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(6-(((6-fluoroquinolin-2-yl)methyl)amino)bicyclo(3.1.0)hex-3-yl)-n-hydroxypyrimidine-5-carboxamide
- chr3996
- chr 3996
- chr-3996
- chr-3996
- chr-3996
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00697879 | Phase 1 | Feb 1, 2008 | Chroma Therapeutics, Erasmus University Rotterdam, Royal Marsden Hospital NHS Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chroma Therapeutics | For profit | 1 | 1 | 1 | 2008 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1